U.S. Court in California Allows Antitrust Claims Against Corcept to Proceed in Case Alleging Sham Litigation, Exclusive Dealing, and Kickbacks
- October 03, 2025
The U.S. District Court for the Northern District of California held that Teva Pharmaceuticals adequately alleged an anticompetitive scheme by Corcept Therapeutics and its distributor, Optime Care, to block generic competition for Korlym, a drug used to treat Cushing’s syndrome. The court granted in part and denied in part defendants’ motion to dismiss.
ARTICLE TAGS
You must be logged in to access this content.